Press releases

17 December 2019
Result of AGM

17 December 2019
AGM Statement

20 November 2019
Notice of AGM

05 November 2019
Sareum notes Sierra Oncology Q3 2019 Results

30 October 2019
Research Update - SDC-1802 Anti-Cancer Poster

17 October 2019
Research Update - AACR-NCI-EORTC abstract

15 October 2019
Final Results for the Year Ended 30 June 2019

07 October 2019
Notice of Full Year Results

27 September 2019
Research Update - TYK2/JAK1 Cancer Programme

27 August 2019
Trading Statement

16 August 2019
Change of Adviser

08 August 2019
Sareum notes Sierra Q2 results

30 July 2019
Additional disclosure concerning Michael Owen

28 June 2019
Additional Funds Raised

27 June 2019
Sierra Seeks Strategic Options for SRA737

26 June 2019
Successful Fundraising

25 June 2019
PrimaryBid.com Offer

25 June 2019
Placing to Progress TYK2/JAK1 Programmes

13 June 2019
Portfolio Update

03 June 2019
Key Takeaways from SRA737 Webcast at ASCO

03 June 2019
Positive SRA737 Data Reported at ASCO

16 May 2019
ASCO Abstracts for SRA737 Published

08 May 2019
Sareum notes Sierra Oncology Q1 2019 Results

30 April 2019
Sareum to Present at BioTrinity 2019 in London

23 April 2019
SRA737 Phase I/IIa data to be presented at ASCO

02 April 2019
Preclinical Data for SRA737 Presented at AACR 2019

12 March 2019
Issue of Options

04 March 2019
Half Yearly Results Ended 31 Dec 2018

28 February 2019
Sierra Oncology has reported its 2018 results

28 February 2019
New SRA737 preclin data to be presented at AACR

23 January 2019
Sierra Oncology to present SRA737 at DDR Tx Summit

15 December 2015
Result of AGM

15 December 2015
CHK1 Clinical Trial Applications

13 November 2015
Notice of AGM

26 October 2015
Final Results

15 September 2015
US and European Patent Grants for Aurora+FLT3

23 July 2015
CHK1 Research Update

First description of the CHK1 clinical development candidate published in peer-reviewed journal: New ‘chemotherapy booster’ could treat lung and pancreatic cancer

17 June 2015
FUNDING AWARD FROM INNOVATE UK

Award of up to £140,000 to investigate the potential of TYK2 inhibitors to treat adolescent leukaemia

28 May 2015
Placing

21 May 2015
Sareum Launches New Website

12 May 2015
Sareum to Present at BioTrinity 2015

07 May 2015
Early Conclusion of Equity Swap Agreement

16 March 2015
Change of Adviser

25 February 2015
Research & Co-Development Collaborations Update

25 February 2015
Half-yearly Report

20 January 2015
Further US Patent Grant for Sareum’s Kinase Inhibitors